Skip to main content
AmigoFish

GLP-1 Agonists in Serious Mental Illness: Current Evidence

From Psychopharmacology and Psychiatry Updates · · 15 min

This plays from the publisher's own server. We do not host a copy.

Open at the source

Not rated yet

Description

In this episode, we explore whether GLP-1 agonists like semaglutide can tackle the metabolic toll of antipsychotics in schizophrenia. Can a drug famous for celebrity weight loss actually protect our most vulnerable psychiatric patients from diabetes and obesity before the damage is done?

Faculty: Oliver Freudenreich, M.D., F.A.C.L.P. Host: Richard Seeber, M.D.

- Learn more about our membership here

- Earn 0.75 CMEs: Quick Take Vol. 84

- GLP-1s in Schizophrenia: Should Semaglutide Be Added for Metabolic Management?

Back to Psychopharmacology and Psychiatry Updates · Report a problem